Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron)

BMJ Open

Volumn 5, Issue 8, 2015, Pages

  Ong, Sim Yee ^a,b   Dolling, Lara ^a   Dixon, Jeannette L ^c   Nicoll, Amanda J ^d,e   Gurrin, Lyle C ^f   Wolthuizen, Michelle ^a   Wood, Erica M ^g   Anderson, Greg J ^c   Ramm, Grant A ^c   Allen, Katrina J ^a,h   Olynyk, John K ⁱ   Crawford, Darrell ^j   Kava, Jennifer ^k   Ramm, Louise E ^c   Gow, Paul ^l   Durrant, Simon ^m   Powell, Lawrie W ^m   Delatycki, Martin B ^a,l  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d Department of Gastroenterology Eastern Health ^*  (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h ROYAL CHILDREN'S HOSPITAL   (Australia)

ⁱ FIONA STANLEY HOSPITAL   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k FREMANTLE HOSPITAL   (Australia)

^l AUSTIN HEALTH   (Australia)

^m ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; FERRITIN; HEMOCHROMATOSIS PROTEIN; IRON; ISOPROSTANE DERIVATIVE; MEMBRANE PROTEIN; TYROSINE; UNCLASSIFIED DRUG; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTHRITIS IMPACT MEASUREMENT SCALE 2 SHORT FORM; ARTICLE; ASSESSMENT OF HUMANS; AUSTRALIA; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ELASTOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; FIBROMETER; HEMOCHROMATOSIS; HEPASCORE; HEREDITARY HEMOCHROMATOSIS; HOMOZYGOTE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IRON OVERLOAD; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MODIFIED FATIGUE IMPACT SCALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SERUM; SHAM PROCEDURE; SHORT FORM 36; SINGLE BLIND PROCEDURE; SYMPTOM; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; URINALYSIS; ADOLESCENT; APHERESIS; BLOOD; CLINICAL TRIAL; ERYTHROCYTE TRANSFUSION; GENETICS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD COMPONENT REMOVAL; ERYTHROCYTE TRANSFUSION; FERRITINS; HEMOCHROMATOSIS PROTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON OVERLOAD; MEMBRANE PROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941630918     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008938     Document Type: Article

References (44)

1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
2. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-30.
3. Bacon BR, Adams PC, Kowdley KV, et al. American Association for the Study of Liver D. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328-43.
4. EASL. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
5. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroeneterology 1991;101:368-72.
6. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
7. Bardou-Jacquet E, Morcet J, Manet G, et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol 2015;62:682-9.
8. Allen KJ, Bertalli NA, Osborne NJ, et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology 2010;52:925-33.
9. Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;103:2914-19.
10. Adams PC, Deugnier Y, Moirand R, et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
11. McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2, 851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
12. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005;366:314-16.
13. McLaren GD, McLaren CE, Adams PC, et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol 2008;22:923-30.
14. Lowry TJ, Pakenham KI. Health-related quality of life in chronic fatigue syndrome: predictors of physical functioning and psychological distress. Psychol Health Med 2008;13:222-38.
15. Niewiadomski O, Rode A, Bertalli N, et al. The effectiveness of venesection therapy for haemochromatosis symptoms. J Liver Dis Transplant 2013;2:1-5.
16. Delatycki MB, Gurrin LC, Ong SY, et al. Reduced mortality due to phlebotomy in moderately iron-loaded HFE Haemochromatosis? The need for clinical trials. J Hepatol 2015;63:282-3.
17. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32.
18. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994;18(Suppl 1):S79-83.
19. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
20. Meiser B, Dunn S, Dixon J, et al. Psychological adjustment and knowledge about hereditary hemochromatosis in a clinic-based sample: a prospective study. J Genet Couns 2005;14:453-63.
21. Power TE, Adams PC, Barton JC, et al. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test 2007;11:55-64.
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
23. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77.
24. McDowell I. Measuring health: a guide to rating scales and questionnaires. 3rd edn. New York: Oxford University Press, 2006.
25. Ren XS, Kazis L, Meenan RF. Short-form Arthritis Impact Measurement Scales 2: tests of reliability and validity among patients with osteoarthritis. Arthritis Care Res 1999;12:163-71.
26. ten Klooster PM, Veehof MM, Taal E, et al. Confirmatory factor analysis of the Arthritis Impact Measurement Scales 2 short form in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:692-8.
27. Andersen ES, Christensen PB, Weis N. Transient elastography for liver fibrosis diagnosis. Eur J Intern Med 2009;20:339-42.
28. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-74.
29. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008;134:1670-81.
30. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007;5:1214-20.
31. Adhoute X, Foucher J, Laharie D, et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 2008;32:180-7.
32. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
33. Di Marco V, Bronte F, Cabibi D, et al. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE)-lack of interference by iron deposition. Br J Haematol 2010;148:476-9.
34. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
35. Guechot J, Lasnier E, Sturm N, et al. group AHEFs. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chem Acta 2010;411:86-91.
36. Pankow JS, Boerwinkle E, Adams PC, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res 2008;152:3-10.
37. Cales P, Boursier J, Bertrais S, et al. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem 2010;43:1315-22.
38. Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009;29:1507-15.
39. Cales P, Boursier J, Ducancelle A, et al. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver Int 2014;34:907-17.
40. Broedbaek K, Poulsen HE, Weimann A, et al. Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med 2009;47:1230-3.
41. Houglum K, Ramm GA, Crawford DH, et al. Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology 1997;26:605-10.
42. Kom GD, Schwedhelm E, Nielsen P, et al. Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: a case-control study. Free Radic Biol Med 2006;40:1194-200.
43. Shizukuda Y, Bolan CD, Nguyen TT, et al. Oxidative stress in asymptomatic subjects with hereditary hemochromatosis. Am J Hematol 2007;82:249-50.
44. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008;10:1405-34.